Potential Therapeutic Application of Host Defense Peptides

Methods in Molecular Biology

Volumn 618, Issue , 2010, Pages 303-327

  Zhang, Lijuan ^a   Falla, Timothy J ^b  

^a Helix Biomedix Inc   (United States)

^b NONE

Author keywords

anti infectives; anti sepsis; antifungals; antimicrobial peptides; HDPs; Host defense peptides; immunomodulators; topical therapeutics

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

ANIMAL; ARTICLE; BACTERIAL SKIN DISEASE; HUMAN; IMMUNOLOGY; METABOLISM; SEPSIS;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; SEPSIS; SKIN DISEASES, BACTERIAL;

EID: 77950499848     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-60761-594-1_19     Document Type: Chapter

References (108)

1. Reddy, K. V., Yedery, R. D., and Aranha, C. (2004) Antimicrobial peptides: premises and promises. Int. J. Antimicrob. Agents 24, 536–547.
2. Hancock, R. E. (1997) Peptide antibiotics. Lancet 349, 418–422.
3. Toke, O. (2005) Antimicrobial peptides: new candidates in the fight against bacterial infec-tions. Biopolymers 80, 717–735.
4. Toke, O., Cegelski, L., and Schaefer, J. (2006) Peptide antibiotics in action: inves-tigation of polypeptide chains in insolu-ble environments by rotational-echo double resonance. Biochim. Biophys. Acta 1758, 1314–1329.
5. Selsted, M. E., Novotny, M. J., Morris, W. L., Tang, Y. Q., Smith, W., and Cullor, J. S. (1992) Indolicidin, a novel bactericidal tride-capeptide amide from neutrophils. J. Biol. Chem. 267, 4292–4295.
6. Rozek, A., Friedrich, C. L., and Han-cock, R. E. (2000) Structure of the bovine antimicrobial peptide indolicidin bound to dodecylphosphocholine and sodium dodecyl sulfate micelles. Biochemistry 39, 15765–15774.
7. Askou, H. J., Jakobsen, R. N., and Fojan, P. (2008) An atomic force microscopy study of the interactions between indolicidin and sup- ported planar bilayers. J. Nanosci. Nanotech-nol. 8, 4360–4369.
8. Shaw, J. E., Alattia, J. R., Verity, J. E., Prive, G. G., and Yip, C. M. (2006) Mecha-nisms of antimicrobial peptide action: studies of indolicidin assembly at model membrane interfaces by in situ atomic force microscopy. J. Struct. Biol. 154, 42–58.
9. Shaw, J. E., Epand, R. F., Hsu, J. C., Mo, G. C., Epand, R. M., and Yip, C. M. (2008) Cationic peptide-induced remod-elling of model membranes: direct visualiza-tion by in situ atomic force microscopy. J. Struct. Biol. 162, 121–138.
10. Otvos, L., Jr. (2005) Antibacterial peptides and proteins with multiple cellular targets. J. Pept. Sci. 11, 697–706.
11. Selsted, M. E. and Ouellette, A. J. (2005) Mammalian defensins in the antimicro-bial immune response. Nat. Immunol. 6, 551–557.
12. Radhakrishnan, Y., Hamil, K. G., Yenugu, S., Young, S. L., French, F. S., and Hall, S. H. (2005) Identification, characterization, and evolution of a primate beta-defensin gene cluster. Genes Immun. 6, 203–210.
13. Zanetti, M., Gennaro, R., and Romeo, D. (1995) Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 374, 1–5.
14. Nizet, V. and Gallo, R. L. (2003) Cathe-licidins and innate defense against invasive bacterial infection. Scand. J. Infect. Dis. 35, 670–676.
15. Hilton, K. B. and Lambert, L. A. (2008) Molecular evolution and characterization of hepcidin gene products in vertebrates. Gene 415, 40–48.
16. Rieg, S., Steffen, H., Seeber, S., et al. (2005) Deficiency of dermcidin-derived antimicro-bial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. J. Immunol. 174, 8003–8010.
17. Oppenheim, F. G., Xu, T., McMillian, F. M., et al. (1988) Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J. Biol. Chem. 263, 7472–7477.
18. Chan, D. I., Hunter, H. N., Tack, B. F., and Vogel, H. J. (2008) Human macrophage inflammatory protein 3alpha: protein and peptide nuclear magnetic resonance solu-tion structures, dimerization, dynamics, and anti-infective properties. Antimicrob. Agents Chemother. 52, 883–894.
19. Maerki, C., Meuter, S., Liebi, M., et al. (2009) Potent and broad-spectrum antimi-crobial activity of CXCL14 suggests an immediate role in skin infections. J. Immunol. 182, 507–514.
20. Radek, K. A., Lopez-Garcia, B., Hupe, M., et al. (2008) The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury. J. Invest. Der-matol. 128, 1525–1534.
21. Egesten, A., Eliasson, M., Johansson, H. M., et al. (2007) The CXC chemokine MIG/CXCL9 is important in innate immunity against Streptococcus pyogenes. J. Infect. Dis. 195, 684–693.
22. Eliasson, M., Frick, I. M., Collin, M., Sorensen, O. E., Bjorck, L., and Egesten, A. (2007) M1 protein of Streptococcus pyogenes increases production of the antibac-terial CXC chemokine MIG/CXCL9 in pha-ryngeal epithelial cells. Microb. Pathog. 43, 224–233.
23. Linge, H. M., Collin, M., Nordenfelt, P., Morgelin, M., Malmsten, M., and Egesten, A. (2008) The human CXC chemokine granulocyte chemotactic protein 2 (GCP-2)/CXCL6 possesses membrane-disrupting properties and is antibacterial. Antimicrob. Agents Chemother. 52, 2599–2607.
24. Collin, M., Linge, H. M., Bjartell, A., Giwer-cman, A., Malm, J., and Egesten, A. (2008) Constitutive expression of the antibac-terial CXC chemokine GCP-2/CXCL6 by epithelial cells of the male repro-ductive tract. J. Reprod. Immunol. 79, 37–43.
25. Linge, H. M., Collin, M., Giwercman, A., Malm, J., Bjartell, A., and Egesten, A. (2008) The antibacterial chemokine MIG/CXCL9 is constitutively expressed in epithelial cells of the male urogenital tract and is present in seminal plasma. J. Interferon Cytokine Res. 28, 191–196.
26. Di Nardo, A., Yamasaki, K., Dorschner, R. A., Lai, Y., and Gallo, R. L. (2008) Mast cell cathelicidin antimicrobial peptide prevents invasive group A Streptococcus infection of the skin. J. Immunol. 180, 7565–7573.
27. De Benedetto, A., Agnihothri, R., McGirt, L. Y., Bankova, L. G., and Beck, L. A. (2009) Atopic dermatitis: a disease caused by innate immune defects? J. Invest. Dermatol. 129, 14–30.
28. Howell, M. D., Wollenberg, A., Gallo, R. L., et al. (2006) Cathelicidin deficiency predis-poses to eczema herpeticum. J. Allergy Clin. Immunol. 117, 836–841.
29. Howell, M. D., Jones, J. F., Kisich, K. O., Streib, J. E., Gallo, R. L., and Leung, D. Y. (2004) Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J. Immunol. 172, 1763–1767.
30. Lee, P. H., Ohtake, T., Zaiou, M., et al. (2005) Expression of an additional catheli-cidin antimicrobial peptide protects against bacterial skin infection. Proc. Natl. Acad. Sci. USA 102, 3750–3755.
31. Schittek, B., Paulmann, M., Senyurek, I., and Steffen, H. (2008) The role of antimicro-bial peptides in human skin and in skin infec-tious diseases. Infect. Disord. Drug Targets 8, 135–143.
32. Lee, D. Y., Yamasaki, K., Rudsil, J., et al. (2008) Sebocytes express functional catheli-cidin antimicrobial peptides and can act to kill Propionibacterium acnes. J. Invest. Dermatol. 128, 1863–1866.
33. McInturff, J. E., Wang, S. J., Machleidt, T., et al. (2005) Granulysin-derived peptides demonstrate antimicrobial and anti-inflammatory effects against Propionibac-terium acnes. J. Invest. Dermatol. 125, 256–263.
34. Temple, M. E. and Nahata, M. C. (2000) Pharmacotherapy of lower limb diabetic ulcers. J. Am. Geriatr. Soc. 48, 822–888.
35. Iwatsuki, K., Yamasaki, O., Morizane, S., and Oono, T. (2006) Staphylococcal cutaneous infections: invasion, evasion and aggression. J. Dermatol. Sci. 42, 203–214.
36. Jacobsen, F., Mohammadi-Tabrisi, A., Hirsch, T., et al. (2007) Antimicrobial activity of the recombinant designer host defence peptide P-novispirin G10 in infected full-thickness wounds of porcine skin. J. Antimi-crob. Chemother. 59, 493–498.
37. Lamb, H. M. and Wiseman, L. R. (1998) Pexiganan acetate. Drugs 56, 1047–1052, discussion 1053–1054.
38. Lipsky, B. A., Holroyd, K. J., and Zasloff, M. (2008) Topical versus systemic antimi-crobial therapy for treating mildly infected diabetic foot ulcers: a randomized, con-trolled, double-blinded, multicenter trial of pexiganan cream. Clin. Infect. Dis. 47, 1537–1545.
39. Chung, W. O., Dommisch, H., Yin, L., and Dale, B. A. (2007) Expression of defensins in gingiva and their role in periodontal health and disease. Curr. Pharm. Des. 13, 3073–3083.
40. Aas, J. A., Paster, B. J., Stokes, L. N., Olsen, I., and Dewhirst, F. E. (2005) Defining the normal bacterial flora of the oral cavity. J. Clin. Microbiol. 43, 5721–5732.
41. Dale, B. A. and Fredericks, L. P. (2005) Antimicrobial peptides in the oral environ-ment: expression and function in health and disease. Curr. Issues Mol. Biol. 7, 119–133.
42. Vankeerberghen, A., Nuytten, H., Dierickx, K., Quirynen, M., Cassiman, J. J., and Cuppens, H. (2005) Differential induction of human beta-defensin expression by periodontal commensals and pathogens in periodontal pocket epithelial cells. J. Periodontol. 76, 1293–1303.
43. Putsep, K., Carlsson, G., Boman, H. G., and Andersson, M. (2002) Deficiency of antibac-terial peptides in patients with morbus Kost-mann: an observation study. Lancet 360, 1144–1149.
44. Beckloff, N., Laube, D., Castro, T., et al. (2007) Activity of an antimicrobial peptide mimetic against planktonic and biofilm cul-tures of oral pathogens. Antimicrob. Agents Chemother. 51, 4125–4132.
45. Faraj, J. A., Dorati, R., Schoubben, A., et al. (2007) Development of a peptide-containing chewing gum as a sustained release antiplaque antimicrobial delivery sys-tem. AAPS PharmSciTech 8, 26.
46. Tanida, T., Okamoto, T., Okamoto, A., et al. (2003) Decreased excretion of antimicrobial proteins and peptides in saliva of patients with oral candidiasis. J. Oral Pathol. Med. 32, 586–594.
47. Meyer, J. E., Harder, J., Gorogh, T., et al. (2004) Human beta-defensin-2 in oral cancer with opportunistic Candida infection. Anti-cancer Res. 24, 1025–1030.
48. Helmerhorst, E. J., Reijnders, I. M., van’t Hof, W., Simoons-Smit, I., Veerman, E. C., and Amerongen, A. V. (1999) Ampho-tericin B-and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides. Antimicrob. Agents Chemother. 43, 702–704.
49. Yin, A., Margolis, H. C., Grogan, J., Yao, Y., Troxler, R. F., and Oppenheim, F. G. (2003) Physical parameters of hydroxyap-atite adsorption and effect on candidacidal activity of histatins. Arch. Oral Biol. 48, 361–368.
50. Castagnola, M., Inzitari, R., Rossetti, D. V., et al. (2004) A cascade of 24 histatins (his-tatin 3 fragments) in human saliva. Sugges-tions for a pre-secretory sequential cleavage pathway. J. Biol. Chem. 279, 41436–41443.
51. Torres, S. R., Garzino-Demo, A., Meiller, T. F., Meeks, V., and Jabra-Rizk, M. A. (2009) Salivary histatin-5 and oral fungal colonisation in HIV+ individuals. Mycoses 52, 11–15.
52. Rothstein, D. M., Spacciapoli, P., Tran, L. T., et al. (2001) Anticandida activity is retained in P-113, a 12-amino-acid fragment of his-tatin 5. Antimicrob. Agents Chemother. 45, 1367–1373.
53. Hiemstra, P. S. (2007) The role of epithelial beta-defensins and cathelicidins in host defense of the lung. Exp. Lung Res. 33, 537–542.
54. Bals, R., Wang, X., Wu, Z., et al. (1998) Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J. Clin. Invest. 102, 874–880.
55. Cheung, Q. C., Turner, P. V., Song, C., et al. (2008) Enhanced resistance to bacterial infection in protegrin-1 transgenic mice. Antimicrob. Agents Chemother. 52, 1812–1819.
56. Zhang, L., Parente, J., Harris, S. M., Woods, D. E., Hancock, R. E., and Falla, T. J. (2005) Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrob. Agents Chemother. 49, 2921–2927.
57. Falagas, M. E., Kasiakou, S. K., Tsiodras, S., and Michalopoulos, A. (2006) The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin. Med. Res. 4, 138–146.
58. Vallon-Eberhard, A., Makovitzki, A., Beau-vais, A., Latge, J. P., Jung, S., and Shai, Y. (2008) Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-lys-ala-DAla-lys. Antimicrob. Agents Chemother. 52, 3118–3126.
59. Wang, G., Stange, E. F., and Wehkamp, J. (2007) Host-microbe interaction: mech-anisms of defensin deficiency in Crohn’s disease. Expert Rev. Anti-infect. Ther. 5, 1049–1057.
60. Wehkamp, J., Koslowski, M., Wang, G., and Stange, E. F. (2008) Barrier dysfunc-tion due to distinct defensin deficiencies in small intestinal and colonic Crohn’s disease. Mucosal Immunol. 1(Suppl 1), S67–S74.
61. Chakraborty, K., Ghosh, S., Kole, H., et al. (2008) Bacterial exotoxins downregulate cathelicidin (hCAP18/LL37) and human beta-defensin 1 (HBD-1) expression in the intestinal epithelial cells. Cell Microbiol. 10, 2520–2537.
62. Iqbal, S. M. and Kaul, R. (2008) Mucosal innate immunity as a determinant of HIV susceptibility. Am. J. Reprod. Immunol. 59, 44–54.
63. Kaul, R., Pettengell, C., Sheth, P. M., et al. (2008) The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. J. Reprod. Immunol. 77, 32–40.
64. Valore, E. V., Wiley, D. J., and Ganz, T. (2006) Reversible deficiency of antimicro-bial polypeptides in bacterial vaginosis. Infect. Immun. 74, 5693–5702.
65. Zapata, W., Rodriguez, B., Weber, J., et al. (2008) Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individuals. Curr. HIV Res. 6, 531–538.
66. Cole, A. M. and Cole, A. L. (2008) Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am. J. Reprod. Immunol. 59, 27–34.
67. Bergman, P., Walter-Jallow, L., Broliden, K., Agerberth, B., and Soderlund, J. (2007) The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr. HIV Res. 5, 410–415.
68. Cole, A. M., Hong, T., Boo, L. M., et al. (2002) Retrocyclin: a primate peptide that protects cells from infection by T-and M-tropic strains of HIV-1. Proc. Natl. Acad. Sci. USA 99, 1813–1818.
69. Cole, A. L., Herasimtschuk, A., Gupta, P., Waring, A. J., Lehrer, R. I., and Cole, A. M. (2007) The retrocyclin analogue RC-101 prevents human immunodeficiency virus type 1 infection of a model human cervi-covaginal tissue construct. Immunology 121, 140–145.
70. Aranha, C. C., Gupta, S. M., and Reddy, K. V. (2008) Assessment of cervicovaginal cytokine levels following exposure to micro-bicide Nisin gel in rabbits. Cytokine 43, 63–70.
71. Donald, C. D., Sun, C. Q., Lim, S. D., et al. (2003) Cancer-specific loss of beta-defensin 1 in renal and prostatic carcinomas. Lab. Invest. 83, 501–505.
72. Sun, C. Q., Arnold, R., Fernandez-Golarz, C., et al. (2006) Human beta-defensin-1, a potential chromosome 8p tumor suppres-sor: control of transcription and induction of apoptosis in renal cell carcinoma. Cancer Res. 66, 8542–8549.
73. Bullard, R. S., Gibson, W., Bose, S. K., et al. (2008) Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. Mol. Immunol. 45, 839–848.
74. Gibson, W., Green, A., Bullard, R. S., Eaddy, A. C., and Donald, C. D. (2007) Inhibi-tion of PAX2 expression results in alternate cell death pathways in prostate cancer cells differing in p53 status. Cancer Lett. 248, 251–261.
75. Bose, S. K., Gibson, W., Bullard, R. S., and Donald, C. D. (2008) PAX2 oncogene negatively regulates the expression of the host defense peptide human beta defensin-1 in prostate cancer. Mol. Immunol. 46, 1140–1148.
76. Baker, M. A., Maloy, W. L., Zasloff, M., and Jacob, L. S. (1993) Anticancer efficacy of Magainin 2 and analogue peptides. Cancer Res. 53, 3052–3057.
77. Hansel, W., Leuschner, C., and Enright, F. (2007) Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases. Mol. Cell Endocrinol. 269, 26–33.
78. Leuschner, C., Enright, F. M., Gawronska, B., and Hansel, W. (2003) Membrane disrupting lytic peptide conjugates destroy hor-mone dependent and independent breast cancer cells in vitro and in vivo. Breast Cancer Res. Treat. 78, 17–27.
79. Ghavami, S., Asoodeh, A., Klonisch, T., et al. (2008) Brevinin-2R(1) semi-selectively kills cancer cells by a distinct mechanism, which involves the lysosomal-mitochondrial death pathway. J. Cell. Mol. Med. 12, 1005–1022.
80. Suttmann, H., Retz, M., Paulsen, F., et al. (2008) Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells. BMC Urol. 8, 5.
81. Rodrigues, E. G., Dobroff, A. S., Cavarsan, C. F., et al. (2008) Effective topical treatment of subcutaneous murine B16F10-Nex2 melanoma by the antimicrobial peptide gomesin. Neoplasia 10, 61–68.
82. Xu, N., Wang, Y. S., Pan, W. B., et al. (2008) Human alpha-defensin-1 inhibits growth of human lung adenocarcinoma xenograft in nude mice. Mol. Cancer Ther. 7, 1588–1597.
83. Yang, D., Chertov, O., and Oppenheim, J. J. (2001) Participation of mammalian defensins and cathelicidins in anti-microbial immunity: receptors and activities of human defensins and cathelicidin (LL-37). J. Leukoc. Biol. 69, 691–697.
84. Niyonsaba, F., Suzuki, A., Ushio, H., Nagaoka, I., Ogawa, H., and Oku-mura, K. (2008) The human antimicro-bial peptide dermcidin activates normal human keratinocytes. Br. J. Dermatol. 160, 243–249.
85. Mookherjee, N., Brown, K. L., Bowdish, D. M., et al. (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J. Immunol. 176, 2455–2464.
86. Mookherjee, N., Rehaume, L. M., and Hancock, R. E. (2007) Cathelicidins and functional analogues as antisepsis molecules. Expert Opin. Ther. Targets 11, 993–1004.
87. Book, M., Chen, Q., Lehmann, L. E., et al. (2007) Inducibility of the endogenous antibiotic peptide beta-defensin 2 is impaired in patients with severe sepsis. Crit. Care 11, R19.
88. Torossian, A., Gurschi, E., Bals, R., Vassil-iou, T., Wulf, H. F., and Bauhofer, A. (2007) Effects of the antimicrobial peptide LL-37 and hyperthermic preconditioning in septic rats. Anesthesiology 107, 437–441.
89. Di Nardo, A., Braff, M. H., Taylor, K. R., et al. (2007) Cathelicidin antimicrobial peptides block dendritic cell TLR4 activation and allergic contact sensitization. J. Immunol. 178, 1829–1834.
90. Deslouches, B., Gonzalez, I. A., De Almeida, D., et al. (2007) De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bac-teraemia. J. Antimicrob. Chemother. 60, 669–672.
91. Wakabayashi, H., Takakura, N., Yamauchi, K., and Tamura, Y. (2006) Modulation of immunity-related gene expression in small intestines of mice by oral administration of lactoferrin. Clin. Vaccine Immunol. 13, 239–245.
92. Lienkamp, K., Madkour, A. E., Musante, A., Nelson, C. F., Nusslein, K., and Tew, G. N. (2008) Antimicrobial polymers prepared by ROMP with unprecedented selectivity: a molecular construction kit approach. J. Am. Chem. Soc. 130, 9836–9843.
93. Statz, A. R., Park, J. P., Chongsiri-watana, N. P., Barron, A. E., and Messer-smith, P. B. (2008) Surface-immobilised antimicrobial peptoids. Biofouling 24, 439–448.
94. Willcox, M. D., Hume, E. B., Aliwarga, Y., Kumar, N., and Cole, N. (2008) A novel cationic-peptide coating for the prevention of microbial colonization on contact lenses. J. Appl. Microbiol. 105, 1817–1825.
95. Lai, X. Z., Feng, Y., Pollard, J., et al. (2008) Ceragenins: cholic acid-based mimics of antimicrobial peptides. Acc. Chem. Res. 41, 1233–1240.
96. Epand, R. F., Savage, P. B., and Epand, R. M. (2007) Bacterial lipid composition and the antimicrobial efficacy of cationic steroid com-pounds (Ceragenins). Biochim. Biophys. Acta. 1768, 2500–2509.
97. Chin, J. N., Rybak, M. J., Cheung, C. M., and Savage, P. B. (2007) Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 51, 1268–1273.
98. Van Bambeke, F., Mingeot-Leclercq, M. P., Struelens, M. J., and Tulkens, P. M. (2008) The bacterial envelope as a target for novel anti-MRSA antibiotics. Trends Pharmacol. Sci. 29, 124–134.
99. Rotem, S. and Mor, A. (2009) Antimicro-bial peptide mimics for improved therapeutic properties. Biochim. Biophys. Acta 1788, 1582–1592.
100. Sarig, H., Rotem, S., Ziserman, L., Danino, D., and Mor, A. (2008) Impact of self-assembly properties on antibacte-rial activity of short acyl-lysine oligomers. Antimicrob. Agents Chemother. 52, 4308–4314.
101. Fritsche, T. R., Rhomberg, P. R., Sader, H. S., and Jones, R. N. (2008) Antimi-crobial activity of omiganan pentahydrochlo-ride against contemporary fungal pathogens responsible for catheter-associated infec-tions. Antimicrob. Agents Chemother. 52, 1187–1189.
102. van den Berg, H. R., Khan, N. A., van der Zee, M., et al. (2009) Synthetic oligopep-tides related to the [beta]-subunit of human chorionic gonadotropin attenuate inflammation and liver damage after (trauma) hem-orrhagic shock and resuscitation. Shock 31, 285–291.
103. Benner, R. and Khan, N. A. (2005) Dis-section of systems, cell populations and molecules. Scand. J. Immunol. 62(Suppl 1), 62–66.
104. Falla, T., Harris, S. M., and Zhang, L. (2007) Novel antiinfective for the treatment and prevention of wound infection, ASM Biode-fense and emerging diseases, Washington, DC, February 27th–March 2nd.
105. Zhang, L., Harris, S. M., and Falla, T. J. (2007) Lipohexapeptides as topical therapeutics for fungal infections, 107th American Society of Microbiology General Meeting, Toronto Canada, May 21–25.
106. Mygind, P. H., Fischer, R. L., Schnorr, K. M., et al. (2005) Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 437, 975–980.
107. Ostergaard, C., Sandvang, D., Frimodt-Moller, N., and Kristensen, H. H. (2009) High CSF penetration and potent CSF bacte-ricidal activity of NZ2114 – a novel Plectasin variant – during experimental pneumococcal meningitis. Antimicrob. Agents Chemother. 53, 1581–1585.
108. Robinson, J. A., Shankaramma, S. C., Jetter, P., et al. (2005) Properties and structure-activity studies of cyclic beta-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I. Bioorg. Med. Chem. 13, 2055–2064.